Doseology Announces Launch of Corporate Communications Program

Rhea-AI Summary

Doseology (PINK: DOSEF) launched an Investor Communications Initiative on December 1, 2025 to strengthen disclosure, expand investor engagement, and support its commercial and capital‑markets strategy. The program includes a 3‑month engagement with Guerilla Capital (Dec 1, 2025–Feb 28, 2026) for $30,000 CAD, and a digital media agreement with Maynard Communications (commencing Dec 1, 2025; term listed to May 31, 2026) for $200,000 CAD. The company said the initiative will align reporting with governance standards, broaden retail and institutional visibility, and support commercialization of its oral stimulant platform. Regulatory disclosures state both firms or their principals currently hold Doseology securities and engagements are not at arm’s length; compensation is not tied to stock performance.

Key Figures

Share price: $0.0516 1-day change: -94.84% 52-week range: $0.0516–$1.50 +5 more

8 metrics

Share price $0.0516 Previous close before communications program announcement

1-day change -94.84% Price change over prior 24 hours

52-week range $0.0516–$1.50 DOSEF 52-week low and high

Guerilla Capital fee C$30,000 3-month investor outreach engagement Dec 1, 2025–Feb 28, 2026

Maynard fee C$200,000 Digital media communications agreement Dec 1, 2025–May 31, 2026

Pouch market size US$69.46 billion Global pouch market expected by 2032

Float shares 4,875,057 Shares float in risk context

Days to cover 101.5 days Reported days to cover in risk context

Market Reality Check

Price: $0.6000 Vol: Volume 320 is 0.17x the 2...

low vol

$0.6000 Last Close

Volume Volume 320 is 0.17x the 20-day average of 1,900, indicating limited pre-news activity. low

Technical Last close at 0.0516 is below the 200-day MA of 0.22 and matches the 52-week low.

Peers on Argus

Among close peers, UNIVERSAL IBOGAINE INC (IBOGF) shows a -9% move while others ...

Among close peers, UNIVERSAL IBOGAINE INC (IBOGF) shows a -9% move while others are flat, suggesting DOSEF’s setup looks more stock-specific than part of a broad sector move.

Market Pulse Summary

This announcement describes Doseology’s launch of a structured investor-relations and digital media ...

Analysis

This announcement describes Doseology’s launch of a structured investor-relations and digital media program, including a three-month Guerilla Capital mandate for C$30,000 and a Maynard Communications engagement for C$200,000. Pre-news, DOSEF traded at its 52-week low of $0.0516, well below the $1.50 high, indicating significant prior pressure. Investors may watch how improved disclosure, governance emphasis, and alignment with a projected US$69.46 billion pouch market interact with future operational milestones.

Key Terms

capital-markets, investor-relations, regulatory disclosure, digital media communications, +1 more

5 terms

capital-markets financial

"support the Company’s long-term commercial and capital-markets strategy."

Capital markets are the systems and places where companies, governments and investors buy and sell long-term money instruments like stocks and bonds, along with the banks, exchanges and rules that make those trades possible. They matter to investors because they determine how easily and cheaply organizations can raise money and how quickly investors can buy or sell holdings—like a town marketplace and plumbing system that moves funds to where they’re needed and sets prices that reflect risk and opportunity.

investor-relations financial

"Doseology is implementing a disciplined investor-relations framework intended to:"

A company's investor-relations function is the team and process that communicates financial performance, strategy, and risks to current and potential investors and analysts. Think of it as the company's customer service desk for shareholders: it explains results, answers questions, and manages expectations so investors can judge the company's health and value. Clear investor-relations matter because they reduce uncertainty, affect market trust, and can influence a stock's price and liquidity.

regulatory disclosure regulatory

"Regulatory Disclosure: Guerilla Capital and/or its principals currently hold securities"

Regulatory disclosure is the formal sharing of material information a company must provide to government agencies and the public, such as financial results, risks, legal actions, or major business changes. It matters to investors because these mandatory updates level the playing field—like a team announcing injuries and strategy changes to fans and referees—so investors can make informed decisions and avoid surprises that could move a stock’s price.

digital media communications technical

"a one (1) year digital media communications agreement with Maynard Communications Ltd."

Digital media communications are the ways a company sends and receives messages using online channels—websites, social media, email, apps, streaming and podcasts—like a storefront and megaphone rolled into one. They matter to investors because these channels shape public perception, customer engagement, sales and compliance risk; stronger, clearer digital communication can protect value and signal management competence, while poor messages can harm revenue and share price.

oral delivery formats medical

"demand continues shifting toward cleaner, controlled oral delivery formats,"

Oral delivery formats are the different ways a medicine or supplement is made to be taken by mouth, such as tablets, capsules, liquids, chewables, dissolving films or powders. For investors, the format matters because it affects how easy the product is to manufacture, ship, dose and for patients to use—factors that influence production costs, regulatory requirements, market appeal and sales potential, much like product packaging affects consumer adoption.

AI-generated analysis. Not financial advice.

KELOWNA, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)(“Doseology” or the “Company”) is pleased to announce the launch of its Investor Communications Initiative, designed to strengthen disclosure practices, expand investor engagement, and support the Company’s long-term commercial and capital-markets strategy.

The program includes a three (3) month engagement with Guerilla Capital, with an option to renew, along with a one (1) year digital media communications agreement with Maynard Communications Ltd. Both engagements will commence at management’s discretion, with the intention to proceed in short order.

Program Overview

Doseology is implementing a disciplined investor-relations framework intended to:

• broaden distribution of corporate updates,
• increase visibility across retail and institutional investor channels,
• support consistent disclosure standards, and
• reinforce capital-markets readiness as the Company advances its oral stimulant platform.

Governance and Disclosure Alignment

Operating in a regulated environment requires structured communication and responsible governance. Doseology is aligning its operational progress—including manufacturing oversight, commercialization planning, and regulatory engagement—with enhanced reporting standards expected of a maturing public issuer. This program reflects the Company’s commitment to strengthening its governance foundation and ensuring consistent, transparent communication with the market.

Executive Commentary

Chris Jackson, Chief Executive Officer

“Having previously founded Qtrade, I’ve seen firsthand how essential strong governance and disciplined communication are to a public company’s long-term success. At Doseology, ensuring our disclosures are transparent, timely, and aligned with best practices is a core priority as we continue to strengthen our disclosure practices and advance our strategy.”

Commercialization & Market Trends

Global consumer demand continues shifting toward cleaner, controlled oral delivery formats, with functional and stimulant pouch products gaining significant traction across major markets.

Patrick Sills, Doseology Head of Commercialization, formerly with Joint Venture between Swedish Match AB and Philip Morris International Inc. (PMI)

“In my experience under the JV SMPM International, I witnessed how quickly oral formats reshaped modern consumption and created a new ritual. With the global pouch market expected to exceed US$ 69.46 billion by 2032* and functional stimulant formats outpacing traditional energy categories, Doseology’s next-generation stimulant platform is directly aligned with these high-growth trends and strategically positioned within this rapidly evolving category.”

*Persistence Market Research - Nicotine Pouches Market Size, Share & Future Trends, 2032

Guerilla Capital Engagement

Doseology has engaged Guerilla Capital to provide:

• investor outreach and communication support,
• engagement across digital investor communities and online platforms,
• capital-markets advisory and messaging guidance, and
• enhanced distribution of corporate updates to retail audiences.

Term: 3 months (renewable at the Company’s option) commencing on December 1, 2025 and ending on February 28, 2026.
Compensation: $30,000 CAD

Ryan Yanch, Independent Investor and Principal of Guerilla Capital

“As an investor and now on behalf of Guerilla Capital, we’ve seen Doseology demonstrate a commitment to consistent communication and responsible reporting. Strengthening investor engagement is an important step forward as the Company continues executing on its strategy.”

Regulatory Disclosure:

Guerilla Capital and/or its principals currently hold securities of Doseology; this engagement is not at arm’s length. Compensation is not tied to stock performance.

The contact information for Guerilla Capital is 84 Watson’ Lane, Dundas, ON L9H 1T3, T: 416-832-1874 and E: ryan@guerillacapital.io.

Maynard Communications Ltd. Engagement

Doseology has entered into a one-year agreement with Maynard Communications Ltd. to support:

• digital advertising and content distribution,
• amplification of corporate developments across Maynard investor channels,
• enhanced retail visibility, and
• broader media exposure within capital markets.

Term: 6 months (renewable at the Company’s option) commencing on December 1, 2025 and ending on May 31, 2026.
Compensation: $200,000 CAD

Regulatory Disclosure:

Maynard Communications Ltd. and/or its principals currently hold securities of Doseology; this engagement is not at arm’s length. Compensation is not tied to stock performance.

The contact information for Maynard Communications Ltd. is Blk A, 15/F Hill, Fer Commercial Building. 65-67 Bonham East Sheung Wan Hong Kong, T: +001.44.656.6777 and E: info@maynardcom.com.

Doseology is committed to keeping the market informed of its progress and believes that this enhanced communication strategy will contribute to building long-term value for its shareholders.

About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)

Doseology Sciences Inc. is a biotechnology-driven consumer products company developing IP-backed oral stimulant technologies designed for cleaner profiles, precise delivery, and performance-focused functionality. Anchored by a commitment to rigorous scientific research and advanced formulation technologies, Doseology is dedicated to leading the industry in creating breakthrough oral stimulant products with meaningful consumer benefits. Doseology is focused on building long-term enterprise value through innovation, regulatory alignment, and the commercialization of differentiated stimulant products.

Website: www.doseology.com

Forward Looking Statements

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from

those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.

Media Contact Information

Chris Jackson

Email: hello@doseology.com

FAQ

What investor communications program did Doseology announce on December 1, 2025 (DOSEF)?

Doseology launched an Investor Communications Initiative including engagements with Guerilla Capital and Maynard Communications to strengthen disclosure and investor outreach.

How long is the Guerilla Capital engagement for Doseology (DOSEF) and what is the fee?

The Guerilla Capital term is three months from December 1, 2025 to February 28, 2026 with compensation of $30,000 CAD.

What are the terms and compensation for Maynard Communications in Doseology's announcement (DOSEF)?

Maynard Communications' agreement commences December 1, 2025 with a listed term to May 31, 2026 and compensation of $200,000 CAD.

Do Guerilla Capital or Maynard hold Doseology securities as disclosed in the Dec 1, 2025 announcement (DOSEF)?

Yes; regulatory disclosure in the announcement states Guerilla Capital and Maynard and/or their principals currently hold Doseology securities and the engagements are not at arm’s length.

When do the Doseology communications engagements start and can they be renewed (DOSEF)?

Both engagements are scheduled to commence on December 1, 2025; Guerilla Capital is a three‑month renewable term and Maynard’s term is listed as renewable at the company’s option.